2
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Dermatologic
1
Conditions
Breast Neoplasms
71
Neoplasm Metastasis
26
Stomach Neoplasms
12
Carcinoma, Non-Small-Cell Lung
11
Colorectal Neoplasms
10
Neoplasms
8
Brain Neoplasms
8
Adenocarcinoma
6
Triple Negative Breast Neoplasms
5
Pancreatic Neoplasms
4
Ovarian Neoplasms
4
Esophageal Neoplasms
4
Endometrial Neoplasms
4
Salivary Gland Neoplasms
3
Recurrence
3
HER2-positive Breast Cancer
3
Advanced Solid Tumor
3
Advanced Breast Cancer
3
Sarcoma
2
Prostatic Neoplasms
2
Neoplasm, Residual
2
Meningeal Carcinomatosis
2
Melanoma
2
HER2-positive Gastric Cancer
2
Gastrointestinal Neoplasms
2
Colonic Neoplasms
2
Carcinoma, Renal Cell
2
Breast Cancer With Brain Metastasis
2
Adenocarcinoma Of Esophagus
2
Vulvar Neoplasms
1
Interventions
Gemcitabine
61
Cisplatin
39
Oxaliplatin
31
Capecitabine
29
Fluorouracil
22
Leucovorin
20
Irinotecan
12
pembrolizumab
11
130-nm albumin-bound paclitaxel
10
durvalumab
9
Erlotinib Hydrochloride
8
Trastuzumab
7
Bevacizumab
7
Taxes
6
Platinum
6
Magnetic Resonance Spectroscopy
6
Biopsy
6
Albumin-Bound Paclitaxel
6
1,2-diaminocyclohexaneplatinum II citrate
6
Specimen Handling
5
Sorafenib
5
Radiotherapy
5
Docetaxel
5
Carboplatin
5
Immunohistochemistry
4
trifluridine tipiracil drug combination
3
dehydroftorafur
3
atezolizumab
3
Watchful Waiting
3
Tegafur
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gallbladder Neoplasms
×
trastuzumab deruxtecan
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled